Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 12, Issue 7, 2003, Pages 1153-1163

  Bagnato, Francesca ^a   Pozzilli, Carlo ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Combination therapy; IFN ; Immunosuppressive drugs; Magnetic resonance activity; Multiple sclerosis; Neutralising antibodies; Steroids

Indexed keywords

AZATHIOPRINE; B7 ANTIGEN; BETA 2 MICROGLOBULIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; EPITOPE; FC RECEPTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERFERON ANTIBODY; INTERLEUKIN 6; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; NEOPTERIN; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; RECOMBINANT BETA INTERFERON 1A; RECOMBINANT BETA INTERFERON 1B; STEROID; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN BINDING; CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; RECEPTOR BINDING; REVIEW;

EID: 0038106427     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.7.1153     Document Type: Review

References (101)

1. JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular interferon β-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. (2000) 343(13 ):898-904.
2. COMI G, FILIPPI M, BARKHOF F et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357(9268):1576-1582.
3. JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular interferon β 1 a for disease progression in relapsing-remitting multiple sclerosis. Ann. Neurol. (1996) 39(3):285-294.
4. POZZILLI C, BASTIANELLO S, KOUDRAIVTSEVA T et al.: Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short-term study in relapsing-remitting multiple sclerosis. J. Neurol, Neurosurg. Psychiatry (1996) 61(3):251-258.
5. THE PRISMS STUDY GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology (2001) 56(12):1628-1636.
6. PANITCH H, GOODIN DS, FRANCIS G et al.: Randomized, comparative study of interferon b-1a treatment regimen in MS: The EVIDENCE Trial. Neurology (2002) 59(10):1496-1506.
7. DURELLI L, VERDUN E, BARBERO P et al.: Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (2002) 359(9316):1453-1460.
8. KNOBLER RL, GREENSTEIN JI, JOHNSON KP et al.: Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Cytokine Res. (1993) 13(5):333-340.
9. THE IFNB MULTIPLE SCLEROSIS GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Interferon β-1b in the treatment of multiple sclerosis. Final outcome of the randomised controlled trial. Neurology (1995) 45(7):1277-1285.
10. SPECTRIMS STUDY GROUP: Randomized controlled trial of interferon β-1a in secondary progressive MS. Neurology (2001) 56(11):1496-1504.
11. LI DK, ZHAO GJ, PATY DW: Randomized controlled trial of interferon-β-1a in secondary progressive MS: MRI results. Neurology (2001) 56(11):1505-1513.
12. EUROPEAN STUDY ON INTERFERON BETA-1B IN SECONDARY-PROGRESSIVE MS: Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet (1998) 352(9139):1491-1497.
13. LEARY SM, MILLER DH, STEVENSONV VL, BREXPA, CHARD DT THOMPSON AJ: Interferon β-1a in primary-progressive MS: An exploratory, randomized, controlled trial. Neurology (2003) 60(1):44-51.
14. THE IFNB MULTIPLE SCLEROSIS GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: Experience during the first three years. Neurology (1996) 47(4):889-894.
15. ABDUL-AHAD AK, GALAZKA AR, REVEL M, BIFFONI M, BORDEN EC: Incidence of antibodies to interferon-b in patients treated with recombinant human interferon b-b1a from mammalian cells. Cytokines Cell. Mol. Ther. (1997) 3(1):27-32.
16. KIVISAKK P, ALM GV, TAIN WZ, MATUSEVICIUS D, FREDRIKSON S, LINK H: Neutralizing and binding anti-interferon-b-1b (RIFNB-1b) antibodies during RIFNB-1b treatment in multiple sclerosis. Multiple Sclerosis (1997) 3(3):184-190.
17. ANTONELLI G, BAGNATO F, POZZILLI C et al.: Development of neutralizing antibodies in patients with multiple sclerosis treated with IFN-b1a. J. Inteferon Cytokine Res. (1998) 18(5):345-350.
18. ROSS C, CLEMMESEN KM, SVENSON M et al.: Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose, frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. (2000) 48(5):706-712.
19. SCAGNOLARI C, BELLOMI F, TURRIZIANI O et al.: Neutralizing and binding antibodies to IFN-β: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. J. Inteferon Cytokine Res. (2002) 22(2):207-213.
20. PERINI P, FACCHINETT A, BULIAN P et al.: Interferon-β (IFN-β) antibodies in interferon-β-1a and interferon-β-1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β-immunogenicity in vivo. Eur. Cytokine Newt. (2001) 12(1):56-61.
21. PUNGOR E, FILES JG, GABE JD et al.: A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J. Interferon Cytokine Res. (1998) 18(12):1025-1030.
22. FERNANDEZ O, MAYORGA C, LUQUE G et al.: Study of binding and neutralizing antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients. J. Neurol. (2001) 248(5):383-388.
23. DEISENHAMMER F, REINDL M, HARVEY J, GASSE T, DILTZE, BERGER T: Bioavailability of interferon β 1b in MS patients with and without neutralizing antibodies. Neurology (1999) 52(6):1239-1243.
24. ZANG YC, YANG D, HONG J, TEJADA-SIMON MV, RIVERA VM, ZHANG JZ: Immunoregulation and blocking antibodies induced by interferon β treatment in MS. Neurology (2000) 55(3):397-404.
25. PERINI P, WADHWA M, BUTTARELLO M et al.: Effect of IFN β and anti-IFNβ antibodies on NK cells in multiple sclerosis patients. J. Neuroimmunol. (2000) 105(1):91-95.
26. RUDICK RA, SIMONIAN NA, ALAM JA et al.: Incidence and significance of neutralizing antibodies to interferon β-1 a in multiple sclerosis. Neurology (1998) 50(5):1226-1272.
27. RICE GPA, PASZNER B, OGER J, LESAUX RN, PATY D, EBERS G: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferonβ-1b. Neurology (1999) 52(6):1277-1279.
28. POLMAN C, KAPPOS L, WHITE R et al.: Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology (2003) 60(1):37-43.
29. PETKAU J, WHITE R: Neutralizing antibodies and The efficacy of interferon β-1b in relapsing-remitting multiple sclerosis. Mult. Scler. (1997) 3(6):402.
30. ARNASON BG, DIANZANI F: Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: Summary of an international workshop on anti-interferon antibodies. J. Interferon Cytokine Res. (1998) 18(8):639-644.
31. PRISMS STUDY GROUP. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet (1998) 352(9139):1498-1504.
32. CLANET M, RADUE EW, KAPPOS L et al.: A randomized double blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology (2002) 59(10):1507-1517.
33. COOK SD, QUINLESS JR, JIOTKWITZ A, BEATON P: Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology (2001) 57(6):1080-1084.
34. VALLITTU AM, HALMINEN M, PELTONIEMI J et al.: Neutralizing antibodies reduce MxA protein induction in interferon-β-1a-treated MS patients. Neurology (2002) 58(12):1786-1790.
35. RONNI T, MELEN K, MALYGIN A, JULKUNEN I: Control of IFN-inducible MxA gene expression in human cells. J. Immunol. (1993) 150(5):1715-1726.
36. The Molecular Biology of Cytokines. T Megaer (Ed.), John Wiley & Sons Ltd (1998):175.
37. 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effect of interferon-alpha treatment. Clin. Exp. Immunol. (1992) 87:340-345.
38. GREY H, KUBO RT, COLON SM et al.: The small subunit of HLA antigens in β2 microglobulin. J. Exp. Med. (1973) 138(6):1608-1610.
39. DE MAYER E, DE MAYER-GIUGNARD J: The Interferon Gene Family. Interferons and Other Regulatory Cytokines. Wiley Interscience, New York (1998):5-38.
40. FUCHS D, WEISS G, REIBNEGGER G, WATECHER H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit. Rev. Clin. Lab. Sci. (1992) 29(3-4):307-341.
41. KHADEMI M, WALLSTROM E, ANDERSSON M et al.: Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon β-1a treatment of multiple sclerosis. J. Neuroimmunol. (2000) 103(2 ):202-210.
42. KRACKE A, VON WUSSOV P, AL-MASRI AN, DALLEY G, WINDHAGEN A, HEIDENREICH F: Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS. Neurology (2000) 54(1):193-199.
43. WILLIAMS GJ, WITT PL: Comparative study of the pharmacodynamic and pharmacological effects of Betaseron and Avonex. J. Interferon Cytokine Res. (1998) 18(11):967-975.
44. CHIANG J, GLOFF CA, YOSHIZAWA CN, WILLIAMS GJ: Pharmacokinetics of recombinant human interferon-β volunteers and its effect on serum neopterin. Pharm. Res. (1993) 10(4):567-572.
45. MUNAFO A, TRINCHARD-LUGAN I, NGUYEN TXQ BURAGLIO M: Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon β-1a after intramuscular and subcutaneous administration. Eur J. Neurol. (1998) 5(2):187-193.
46. ROTHUIZEN LE, BUCLIN T, SPERTINI F et al.: Influence of Interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J. Neuroimmunol. (1999) 99(1):131-141.
47. ALAM J, GOELZ S, RIOUX P et al.: Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon β-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers. Pharm. Res. (1997) 14(14):546-549.
48. STURZEBECHER S, MAIBAUER R, HEUNER A, BECKMANN K, AUFDEMBRINKE B: Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J. Interferon Cytokine Res. (1999) 19(11):1257-1264.
49. BAGNATO F, POZZILLI C, SCAGNOLARI C et al.: A one-year study on the pharmacodynamic profile of interferon β-1a in multiple sclerosis. Neurology (2002) 58(9):1409-1411.
50. DEISENHAMMER. F, MAYRINGER I, HAREVY J et al.: A comparative study of the relative bioavailability of different interferon β preparations. Neurology (2000) 54(11):2055-2060.
51. THE MUSCLE STUDY GROUP: Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis. Neurology (2001) 57(9):1566-1570.
52. FIERLBECK G, ULMER A, SCHREINER T, STROEBEL W, SCHIEBEL U, BRZOSKA J: Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma. J. Interferon Cytokine Res. (1996) 16(10):777-781.
53. ZIPP F, WELLER M, CALABRESI PA et al.: Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. (1998) 43(1):116-120.
54. KASTRUKOFF LF, MORGAN NG, ZECCHINI D et al.: Natural killer cells in relapsing-remitting MS: effect of treatment with interferon β-1B. Neurology (1999) 52(2):351-359.
55. Roitt's Essential Immunology (9th Ed.). IM Roitt (Ed.), Blackwell Science Ltd, Oxford, England (1997):168-177.
56. LASSMANN H: The pathology of multiple sclerosis and its evolution. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (1999) 354(1390):1635-1640.
57. LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. (2000) 47(6):707-717.
58. PRINEAS JW, WRIGHT RG: Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. (1978) 38(4):409-421.
59. ARCHELOS JJ, STORCH MK, HARTUNG HP: The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. (2000) 47(6):694-706.
60. ESIRI MM: Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet (1977) 2(8036):478-480.
61. OZAWA K, SUCHANEK G, BREITSCOPF H et al.: Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 117(Part 6):1311-1322.
62. OEGER J, VOREBEYCHICK G, PATY DW: In betaseron treated MS patients, in vivo immune function can be a predictor of neutralising antibody development. Neurology (1997) 48(4):A80.
63. ZIVADINOV R, RUDICK RA, DE MASI R et al.: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology (2001) 57(7):1239-1247.
64. GOODKIN DE, KINKEL RP, WEINSTOCK-GUTTMANN B et al.: A Phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology (1998) 51(1):239-245.
65. GASPERINI C, POZZILLI C, BASTIANELLO S et al.: Effects of steroids on Gd-enhancing lesions before and during recombinant β interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology (1998) 50(2):403-406.
66. RICHERT ND, OSTUNI JL, BASH CN, LEIST TP, MCFARLAND HF, FRANK JA: Interferon β-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult. Scler. (2001) 7(1):49-58.
67. ROSENBERG GA, DENCOFF JE, CORREA N Jr, REINERS M, FORD CC: Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology (1996) 46(6):1626-1632.
68. ALAMAWI WY, BEYHUM HN, RAHME AA, RIEDER MJ: Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. (1996) 60(5):563-572.
69. POZZILLI C, ANTONINI G, BAGNATO F et al.: Monthly corticosteroids decrease neutralizing antibodies to RIFNβ1 b: a randomized trial in multiple sclerosis. J. Neurol. (2002) 249(1):50-56.
70. WHO: WHO Expert Committee On Biological Standardisation. Thirty-fifth report. WHO Technical Report Series 725. World Health Organisation, Geneva, Switzerland (1985).
71. HRICIK DE, ALMAWI WJ, STROM TB: Trends in the use of glucocorticoids in renal transplantation. Transplantation (1994) 57(7):979-989.
72. ROLAK LA, HARATI Y: Neuroimmunology for the Clinicians. Butterworth-Heinemann, Newton, MA, USA (1998).
73. CALABRESI PA, WILETRDINK JL, ROGG JM, MILLS P, WEBB A, WHARTENBY KA: An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS. Neurology (2002) 58(2):314-317.
74. PATTI F, CATALDI DI ML, NICOLETTI F, REGGIO E, NICOLETTI A, REGGIO A: Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (2001) 71(3):404-407.
75. FERNANDEZ O, GUERRERO M, MAYORGA C et al.: Combination therapy with interferon β-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J. Neurol. (2002) 249(8):1058-1062.
76. SALMAGGI A, CORSINI E, LA MANTIA L et al.: Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J Neurol. (1997) 244(3):167-174.
77. RINKARDT NE, KRUTH SA, KAUSHIK A: The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Can. J. Vet. Res. (1999) 63(1):18-24.
78. KHAN OA, DHIB-JALBUT SS: Neutralizing antibodies to interferon β-1a and interferon β-1b are cross-reactive. Neurology (1998) 51(6):1698-1702.
79. ANTONELLI G, SIMEONI E, BAGNATO F et al.: Further study on the specificity and the incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN β-1a or IFN β-1b. J. Neurol. Sci. (1999) 168(2):131-136.
80. BERTOLOTTO A, MALUCCHI S, MILANO E, CASTELLO A, CAPOBIANCO M, MUTANI N: Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology (2000) 48(2):95-100.
81. KIVISAKK P, ALM GV, FREDRIKSON S, LINK H: Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis. Eur. J. Neurol. (2000) 7(1):27-34.
82. DRESSER DW, MITCHISON NA: The mechanism of immunological paralysis. Adv. Immunol. (1968) 8:129-181.
83. BERTOLOTTO A, MALUCCHI S, SALA A et al.: Differential effects of three interferon β-s on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry (2002) 73(2):148-153.
84. MEDENICA RD, MUKERIEE S, ALONSO K, LAZOVIC G, HUSCHART T: Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis. J. Clin. Apheresis (1994) 9(4):222-227.
85. SORENSEN PS, WANSCHER B, SZPIRT W et al.: Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology (1996) 46(6):1620-1625.
86. SORENSEN PS, FAZEKAS F, LEE M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur. J. Neurol. (2002) 9(6):557-563.
87. SORENSEN PS, WANSCHER B, JENSEN CV et al.: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology (1998) 50(5):1273-1281.
88. VASSILEV T, YAMAMOTO M, AISSAOUI A et al.: Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. (1999) 29(8):2436-2442.
89. STANGEL M, TOYKA KV, GOLD R: Mechanisms of high-dose intravenous immunoglobulins in demyelinating discases. Arch. Neurol. (1999) 56(6):661-663.
90. KISHIMOTO T: The biology of Interleukin-6. Blood (1989) 74(1):1-10.
91. Multiple Sclerosis Therapeutics. RA Rudick, DE Goodkin (Eds), Martin Dunitz, London (1999):309-333.
92. BERNASCONI NL, TRAGGIAI E, LANZAVECCHIA A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 298:2199-2202.
93. BIELEKOVA B, MARTIN R: Multiple sclerosis: immunotherapy. Curr. Treat. Options Neurol. (1999) 1(3):201-220.
94. GOBBINI MI, SMITH ME, RICHERT ND, FRANK JA, McFARLAND HF: Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroimmunol. (1999) 99(1):142-149.
95. KHAN OA, ZVARTAU-HIND M, CAON C et al.: Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult. Scler. (2001) 7(3):185-188.
96. TEN BERGE RJ, VAN WALBEEK HK, SCHELLEKENS PT: Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. Clin. Exp. Immunol. (1982) 50(3):495-502.
97. MOODY DJ, KAGAN J, LIAO D, ELLISON GW, MYERS LW: Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters. J. Neuroimmunol. (1987) 14(2):161-173.
98. LAMERS KJ, UITDEHAAG BM, HOMMES OR, DOESBURG W, WEVERS RA, VON GEEL WJ: The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (1988) 51(10):1334-1337.
99. KUZEL TM, ROENIGK HH Jr, SAMUELSON E, ROSEN ST: Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J. Natl. Cancer Inst. (1992) 84(2):119-121.
100. RAJAN GP, SEIFERT B, PRUMMER O, JOLLER-JEMELKA HI, BURG G, DUMMER R: Incidence and in vivo-relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon-alpha 2a combined with acitretin or PUVA. Arch. Dermatol. Res. (1996) 288(9):543-548.
101. WILES CM, OMAR L, SWAN AV et al.: Total lymphoid irradiation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (1994) 57(2):154-163.